Online inquiry

IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5850MR)

This product GTTS-WQ5850MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5850MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15626MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ7448MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ15478MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ15752MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ7949MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ824MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ9344MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ11230MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI3902
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW